Affimed Announces Clinical Updates at the Annual Meeting of the American Association for Cancer Research
March 08, 2022 16:35 ET
|
Affimed N.V.
In a Clinical Trials Plenary Session an update of the phase 1/2 study evaluating cord blood-derived NK cells that are pre-complexed with the innate cell engager AFM13 in patients with CD30-positive...
Affimed Announces Publication of Preclinical Data Demonstrating Cytotoxic Potency and Efficacy of NK Cells Precomplexed with Innate Cell Engagers after Freezing & Thawing
February 09, 2022 16:05 ET
|
Affimed N.V.
Precomplexing NK cells with Innate Cell Engagers (ICE® molecules) results in a CAR-like NK cell product, whose magnitude and specificity of antibody-dependent cellular cytotoxicity (ADCC) remain...
Affimed to Present at Upcoming Investor Events
February 08, 2022 06:30 ET
|
Affimed N.V.
HEIDELBERG, Germany, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
Affimed Announces Completion of Enrollment in REDIRECT, the Registration-Directed Study of AFM13 in PTCL, and Provides Business Update
January 06, 2022 06:30 ET
|
Affimed N.V.
Enrollment of REDIRECT study (AFM13-202) is completed; topline clinical readout expected in 2H 2022FDA approves protocol amendment to allow for (i) enrollment of up to 40 patients at the highest dose...
Affimed to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022 06:30 ET
|
Affimed N.V.
HEIDELBERG, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 at the 63rd American Society of Hematology Annual Meeting and Exposition
December 13, 2021 09:05 ET
|
Affimed N.V.
AFM28 effectively induces depletion of leukemic cells in patient bone marrow samples and demonstrates the anticipated good safety profile and pharmacologic activity in cynomolgus monkeysPre-complexing...
Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymphoma Patients with Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13
December 09, 2021 06:30 ET
|
Affimed N.V.
For the 13 patients treated at the recommended phase 2 dose (RP2D) the response rate after one cycle of treatment remains at 100% with a 38.5% complete response (CR) rate; one additional patient...
Affimed Initiates Patient Recruitment for a Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Roche’s Anti-PD-L1 Checkpoint Inhibitor Atezolizumab
December 08, 2021 06:30 ET
|
Affimed N.V.
HEIDELBERG, Germany, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 for CD30-positive Lymphomas
November 22, 2021 07:11 ET
|
Affimed N.V.
100% objective response rate with a 42% complete response rate in 12 patients, according to investigator assessment, after the 1st of 2 planned cycles at the recommended phase 2 dose of 108 cord...
Affimed Shares Preclinical Data on Mechanism of Action of two Innate Cell Engagers at the 36th SITC Meeting, Demonstrating their Potential to Induce Antibody Dependent Cellular Phagocytosis and Serial Killing
November 12, 2021 07:01 ET
|
Affimed N.V.
HEIDELBERG, Germany, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...